EPIDERMODYSPLASIA VERRUCIFORMIS: SUATU KASUS JARANG
DOI:
https://doi.org/10.33820/mdvi.v47i4.373Keywords:
epidermodysplasia verruciformis, human papillomavirusAbstract
Epidermodysplasia verruciformis (EV) is a rare genodermatosis characterized by increased
susceptibility to β-human papilloma virus (HPV) infection, especially HPV type -5 and -8 and risk of malignant transformation. This condition can be inherited in an autosomal recessive manner, as well as an acquired
condition. Skin lesions develop early in childhood, presenting as flat warts, seborrheic keratosis-like, or
pityriasis versicolor-like.
This report described a 58 year-old man with history of warts since childhood. There was no history of
parental consanguinity and immunosuppression. Skin lesions are persistent and progressive, manifests as multiple hyperpigmented plaques resembling seborrheic keratosis, some of them has verrucous surfaces and hypopigmented. Histopathology examination showed hyperkeratosis and coilocyte. Treatement consists of topical retinoic acid and sun avoidance.
Diagnosis of EV can be made easily based on the history, physical examination and skin biopsy. HPV serotype testing can help determine the associated EV-HPV type. Several therapeutic modalities have been tried including topical and systemic retinoids, interferon, immunotherapy, electrodesication, cryotherapy and surgery. However, definitive therapy is not yet available.
Early diagnosis, patient education, protection against sunlight and regular monitoring for malignant transformation are important to improve patient’s quality of life.
Downloads
References
2. Imahorn E, Yüksel Z, Spoerri I, Gürel G, Imhof C, Saraçoğlu ZN, dkk. Novel TMC8 splice site mutation in epidermodysplasia verruciformis and review of HPV infections in patients with the disease. J Eur Acad Dermatol Venereol. 2017;31:1722-1726.
3. Otrofanowei E, Akinkugbe A, Ayanlowo O. Management challenges of epidermodysplasia verruciformis in a resource-limited setting: A retrospective review. J Clin Sci. 2017;14:162-6.
4. Shruti S, Siraj F, Singh A , Ramesh V. Epidermodysplasia verruciformis: three case reports and a brief review. Acta Dermatovenereol. 2017;26:59-61.
5. Huang Sꓹ Wu Jꓹ Lewis Dꓹ Rady PL, Tyring SK. A novel approach to the classification of epidermodysplasia verruciformis. Int J Dermatol. 2018;57: 1344-50.
6. Nuovo Gꓹ Nicol Aꓹ de Andrade C, Magro C. New biomarkers of human papillomavirus infection in epidermodysplasia verruciformis. Ann Diagn Pathol. 2019;40:81-7.
7. Przybyszewska J, Zlotogorski Aa, Ramot Y. Re- evaluation of epidermodysplasia verruciformis: reconciling more than 90 years of debate. J Am Acad Dermatol. 2017;76:1161-75.
8. Costa C, Scalvenzi M, Ayala F, Fabbrocini G, Monfrecola G. How to treat actinic keratosis? An update. J Dermatol Case Rep. 2015;9: 29–35.
9. André R, Laffitte E, Abosaleh M, Cortès B, Toutous-Trellu L, Kaya G. Sign of Leser-Trélat and cutaneous T-cell lymphoma: a rare association. Dermatopathology (Basel). 2018;5:69-73.
10. Bhat Y, Ashraf S, Hassan I. Epidermodysplasia verruciformis in two siblings responding to retinoids. Indian J Paediatr Dermatol. 2016;17:322-324.
